Physician profile
David Eric Collins
NPI 1982691705
$34,512.09
in general payments reported to CMS, 2019-2025
40 companies · $4,777 in 2025
The $4,777 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,891 · 2020: $2,843 · 2021: $3,224 · 2022: $6,475 · 2023: $4,699 · 2024: $2,604 · 2025: $4,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,296 · Travel and Lodging: $2,893 · Consulting Fee: $1,888 · Education: $3.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,295.60 |
| Travel and Lodging | $2,892.73 |
| Consulting Fee | $1,887.50 |
| Education | $3.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $4,529.44 | 2019-2025 | Tysabri, Tecfidera |
| Medtronic, INC. | $4,046.59 | 2022-2025 | Percept PC Brainsense |
| Lundbeck LLC | $3,922.61 | 2019 | |
| Livanova USA, INC. | $3,704.41 | 2019-2025 | Vns Therapy |
| Alexion Pharmaceuticals, INC. | $2,226.59 | 2019-2025 | Ultomiris |
| Boston Scientific Corporation | $2,198.76 | 2019-2022 | |
| Medtronic USA, INC. | $2,197.82 | 2019-2020 | |
| Argenx US, INC. | $1,941.99 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Kyowa Kirin, INC. | $1,547.85 | 2020-2021 | |
| Abbvie INC. | $789.38 | 2019-2025 | Ubrelvy, Qulipta, Duopa |
| Genzyme Corporation | $698.64 | 2020-2024 | |
| Emd Serono, INC. | $648.76 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $561.31 | 2019-2024 | |
| Lilly USA, LLC | $515.85 | 2022-2024 | Amyvid, Kisunla, Mounjaro |
| Alnylam Pharmaceuticals INC. | $412.18 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.